Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis

Company Overview

Nykode Therapeutics AS is a clinical-stage biotechnology company headquartered in Oslo, Norway, focused on the discovery and development of next-generation immunotherapies. The company applies its proprietary plasmid DNA platform to create highly targeted vaccines designed to elicit robust and durable immune responses against both cancerous and infectious disease targets. Nykode operates through research and development facilities in Europe and maintains a presence in North America to support its global clinical programs.

The core of Nykode’s technology is its modular, MHC class II-targeting DNA construct platform, which enables precise delivery of antigenic payloads to antigen-presenting cells. By fusing tailored targeting units with disease-specific antigens, the platform aims to enhance T-cell activation and antibody responses. Nykode’s oncology pipeline includes lead candidates such as VB10.16 for HPV16-driven malignancies and VB10.2212 for non-small cell lung cancer, both of which are advancing through clinical trials. In the infectious disease arena, the company has progressed vaccine candidates targeting malaria and other pathogens into early-stage studies.

Originally founded in 2012 under the name Vaccibody ASA, the company rebranded as Nykode Therapeutics AS in 2022 to reflect its evolving strategic focus on modular immunotherapy solutions. Nykode completed its initial public offering on the Oslo Stock Exchange in 2017 and maintains an over-the-counter listing in the United States under the ticker VACBF. Leadership is headed by Chief Executive Officer Asgeir Brekke, supported by a management team with deep expertise in immunology, molecular biology and clinical development.

Nykode pursues strategic collaborations with leading academic institutions and industry partners to accelerate preclinical research and expand its clinical trial footprint. The company’s global network of trial sites spans Europe, North America and select emerging markets, aiming to generate comprehensive safety and efficacy data. Through its integrated R&D approach and modular platform, Nykode Therapeutics is positioned to address unmet medical needs in oncology and infectious disease by harnessing the power of precision immunotherapy.

Key Stats

• Today's Range: $0.21 to $0.21
• 50-Day Range: $0.17 to $0.21
• 52-Week Range: $0.17 to $0.95
• Volume: N/A
• Average Volume: 3,118 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VACBF Stock Analysis - Frequently Asked Questions

How have VACBF shares performed this year?

Nykode Therapeutics AS's stock was trading at $0.2408 at the beginning of 2025. Since then, VACBF shares have decreased by 13.2% and is now trading at $0.2090.

How do I buy shares of Nykode Therapeutics AS?

Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VACBF
• CIK: N/A
• Web: nykode.com
• Phone: 47-22-95-81-93
• Fax: N/A
• Employees: 171
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A